An update on the use of lenalidomide for the treatment of multiple myeloma

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

(2015) A. Keith Stewart et al.   NEW ENGLAND JOURNAL OF MEDICINE

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma

(2014) P. G. Richardson et al.   BLOOD

Front-Line Transplantation Program With Lenalidomide, Bortezomib, and Dexamethasone Combination As Induction and Consolidation Followed by Lenalidomide Maintenance in Patients With Multiple Myeloma: A Phase II Study by the Intergroupe Francophone du Myélome

(2014) Murielle Roussel et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study

(2014) Shaji K Kumar et al.   LANCET ONCOLOGY

Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data

(2014) Antonio Palumbo et al.   LANCET ONCOLOGY

Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma

(2014) Tomer M. Mark et al.   LEUKEMIA & LYMPHOMA

Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma

(2014) Lotfi Benboubker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Autologous Transplantation and Maintenance Therapy in Multiple Myeloma

(2014) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma

(2014) D S Siegel et al.   Blood Cancer Journal

Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma

(2013) M. Wang et al.   BLOOD

Phase Ib Dose-Escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple Myeloma

(2013) R. Niesvizky et al.   CLINICAL CANCER RESEARCH

Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma

(2013) M. A. Dimopoulos et al.   HAEMATOLOGICA

Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients

(2013) A K Nooka et al.   LEUKEMIA

A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide

(2012) M. A. Dimopoulos et al.   BLOOD

Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma

(2012) S. Kumar et al.   BLOOD

A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma

(2012) A. J. Jakubowiak et al.   BLOOD

Phase II Trial of Syncopated Thalidomide, Lenalidomide, and Weekly Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

(2012) Madiha Tufail et al.   Clinical Lymphoma Myeloma & Leukemia

A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma

(2012) J R Berenson et al.   LEUKEMIA

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

(2012) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

(2012) Michel Attal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma

(2012) Philip L. McCarthy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: Results from a phase 2 trial

(2011) Shaji K. Kumar et al.   AMERICAN JOURNAL OF HEMATOLOGY

Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial

(2011) A. J. Jakubowiak et al.   BLOOD

Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS)

(2011) S. Mailankody et al.   BLOOD

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide

(2011) Y. X. Zhu et al.   BLOOD

Lenalidomide Restrains Motility and Overangiogenic Potential of Bone Marrow Endothelial Cells in Patients with Active Multiple Myeloma

(2011) A. De Luisi et al.   CLINICAL CANCER RESEARCH

Lenalidomide is effective as salvage therapy in refractory or relapsed multiple myeloma: analysis of the Spanish Compassionate Use Registry in advanced patients

(2011) Adrián Alegre et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Phase I Trial of Lenalidomide and CCI-779 in Patients With Relapsed Multiple Myeloma: Evidence for Lenalidomide–CCI-779 Interaction via P-Glycoprotein

(2011) Craig C. Hofmeister et al.   JOURNAL OF CLINICAL ONCOLOGY

Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis

(2011) M. CARRIER et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Lenalidomide can induce long-term responses in patients with multiple myeloma relapsing after multiple chemotherapy lines, in particular after allogeneic transplant

(2011) Francesco Spina et al.   LEUKEMIA & LYMPHOMA

Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment

(2010) Ulrike Klein et al.   ANNALS OF HEMATOLOGY

Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)

(2010) J. A. Zonder et al.   BLOOD

The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study

(2010) Stephen A. Schey et al.   BRITISH JOURNAL OF HAEMATOLOGY

Effects of Lenalidomide and Dexamethasone Treatment Duration on Survival in Patients With Relapsed or Refractory Multiple Myeloma Treated With Lenalidomide and Dexamethasone

(2010) Jesús F. San-Miguel et al.   Clinical Lymphoma Myeloma & Leukemia

Activity and safety of lenalidomide and dexamethasone in patients with multiple myeloma requiring dialysis: a Spanish multicenter retrospective study

(2010) Javier De La Rubia et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma

(2010) J.-L. Harousseau et al.   HAEMATOLOGICA

Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma

(2010) A Palumbo et al.   LEUKEMIA

Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone

(2010) H Avet-Loiseau et al.   LEUKEMIA

Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies

(2010) M A Dimopoulos et al.   LEUKEMIA

Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13

(2009) D. Reece et al.   BLOOD

Risky business in myeloma

(2009) S. Lonial   BLOOD

Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom)

(2009) S. Knop et al.   BLOOD

Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone

(2009) P. Kapoor et al.   BLOOD

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma

(2009) P. Richardson et al.   BLOOD

Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma

(2009) Christine Chen et al.   BRITISH JOURNAL OF HAEMATOLOGY

Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma

(2009) Edward A. Stadtmauer et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Mechanism of action of lenalidomide in hematological malignancies

(2009) Venumadhav Kotla et al.   Journal of Hematology & Oncology

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

(2009) S Vincent Rajkumar et al.   LANCET ONCOLOGY

Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma

(2009) M A Dimopoulos et al.   LEUKEMIA

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

(2009) H Quach et al.   LEUKEMIA

Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure

(2008) M. Wang et al.   BLOOD

Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma

(2008) I Breitkreutz et al.   LEUKEMIA